RxDoctor Payments Data

Maya Shammas, MD

Ophthalmology · Lynwood, CANPI 1649438763

Payments from drug & device makers

$168,360in general payments, 2019–2025

Across 212 payments — averaging $794.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$160K
  • Alcon$2K
  • Tarsus Pharmaceuticals, Inc.$2K
  • Glaukos Corporation$1K
  • Amgen$866
  • AbbVie$845
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$1,45017%
  • Speaking & faculty fees$1,45017%
  • Food & beverage$5,42865%
  • Entertainment$380%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$168,360 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$197,617
Medicare patients
419
Services billed
1,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast153$109,125
LumiganBimatoprost128$63,521
XdemvyLotilaner29$53,015
RestasisCyclosporine66$41,417
RocklatanNetarsudil Mesylat/Latanoprost27$22,238
MoxifloxacinMoxifloxacin Hcl683$17,234
Prednisolone Acetate757$16,500
Latanoprost1,641$14,428
RhopressaNetarsudil Mesylate34$13,746
Cyclosporine45$13,032
CombiganBrimonidine Tartrate/Timolol20$11,505
Alphagan PBrimonidine Tartrate34$10,418
Ketorolac Tromethamine694$7,458
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat426$5,759
Travoprost54$4,153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan, Alphagan P$845$126,861248 claims
Bausch & Lomb Americas Inc.Xiidra$23$109,125153 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$1,846$53,01529 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$104$35,98461 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Lynwood

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →